

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7357021

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	SCHRÖDINGER, INC.	05/24/2022
RECEIVING PARTY DATA		
Name:	SCHRÖDINGER, LLC	
Street Address:	1540 BROADWAY	
Internal Address:	24TH FLOOR	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10036	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17825680
CORRESPONDENCE DATA		
Fax Number:	(317)276-3861	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	patents@lilly.com	
Correspondent Name:	ELI LILLY AND COMPANY	
Address Line 1:	P. O. BOX 6288	
Address Line 2:	PATENT DIVISION	
Address Line 4:	INDIANAPOLIS, INDIANA 46206-6288	
ATTORNEY DOCKET NUMBER:	X23034	
NAME OF SUBMITTER:	PATRICIA FOOR	
SIGNATURE:	/Patricia Foor/	
DATE SIGNED:	05/31/2022	
Total Attachments: 3		
source=X23034AssignmentSchrodingerInctoSchrodingerLLC_1#page1.tif		
source=X23034AssignmentSchrodingerInctoSchrodingerLLC_1#page2.tif		
source=X23034AssignmentSchrodingerInctoSchrodingerLLC_1#page3.tif		

ASSIGNMENT

Assignor: Schrödinger, Inc.
a corporation organized and existing under the laws of Delaware,
and having a place of business at:
1540 Broadway, 24th Floor
New York, NY 10036

Assignee: Schrödinger, LLC
a corporation organized and existing under the laws of Delaware,
and having a place of business at:
1540 Broadway, 24th Floor
New York, NY 10036

Country	Application No.	Filing Date	Title
WIPO	PCT/US2022/031112	May 26, 2022	ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
United States	17/825680	May 26, 2022	ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
United States	63/193,917	May 27, 2021	ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
United States	63/227,493	July 30, 2021	ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
United States	63/250,592	September 30, 2021	ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
United States	63/253,352	October 7, 2021	ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE

1. Assignor represents that it is the owner of the patents and patent applications listed above, and of all foreign and domestic patents, patent applications, including continuation-in-part applications, reissues, re-examinations, certificates of invention, and the like that derive priority from, or claim the benefit of the filing date of, the patents and patent applications listed above (the "Patents and Patent Applications") and of all new and useful inventions and improvements that are disclosed in the Patents and Patent Applications (the "Inventions"). The Patents and Patent Applications and the Inventions are collectively referred to as the "Patent Assets."
2. Assignor hereby assigns to Assignee its entire worldwide right, title, and interest in and to the Patent Assets, including the right to file and prosecute, in Assignee's name wherever so permitted by law or in the name of Assignor wherever necessary, patent applications, including corresponding and continuing applications, reissues, re-examinations, certificates of invention,

and the like based on any of the Patent Assets, and to claim priority to any of the Patents and Patent Applications pursuant to the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes.

3. Assignor shall, when requested by Assignee and at no cost to Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and powers of attorney to Assignee or to agents and legal representatives of Assignee, and all other papers necessary and proper to carry out the intent and purpose of this Assignment, (ii) execute all papers necessary in connection with the Patents and Patent Applications, and any continuing, divisional, reissue, reexamination or other corresponding application thereof or post-grant proceeding relating thereto and to execute any separate assignment in connection with any such application as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions.
4. Assignor hereby assigns to Assignee (a) all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, including choses in action, that Assignor has or may have against any party for infringement of the Patents and Patent Applications and (b) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Patent Assets, and any other rights assigned by this Assignment.
5. Assignor represents that Assignor has the full right to convey the interests assigned by this Assignment, and that Assignor has not executed and will not execute any agreement in conflict with this Assignment.
6. This Assignment is binding upon and inures to the benefit of the successors and assigns of the parties.
7. To the extent any portion of the rights assigned by this Assignment has previously been assigned to the Assignee, this Assignment is a confirmation of the previous assignment.
8. Assignor acknowledges receipt of fair and adequate consideration for this Assignment.

[ASSIGNMENT CONTINUES ON SIGNATURE PAGE]

The Assignor hereby executes this Assignment.

Assignor: Schrödinger, Inc.

Signature: / DocuSigned by: Ramy Farid / Date: May 24, 2022

[9530F280F31405...
Name: Ramy Farid

Title: President & CEO

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: Schrödinger, LLC

Signature: / DocuSigned by: Ramy Farid / Date: May 24, 2022

[9530F280F31405...
Name: Ramy Farid

Title: President & CEO